New Law Requires Disclosure of Biologic Patent Settlement Agreements to Antitrust Authorities

Click here to read the full article online

Last week, the Patient Right to Know Drug Prices Act (""Act"") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar companies that relate to the manufacture, marketing, or sale of biologic and biosimilar products.